The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Thromboembolism (TE) and association with survival in patients (pts) with melanoma receiving chemo– or immunotherapy.
 
Tamara A. Sussman
No Relationships to Disclose
 
Long Vu
No Relationships to Disclose
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I)
Consulting or Advisory Role - Apexigen; Bristol-Myers Squibb; Nektar; Shionogi
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Patrick Alexander Ott
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Oncorus; Pfizer (Inst); Xencor
Expert Testimony - Boehringer Ingelheim
 
Sarah C. Markt
No Relationships to Disclose
 
Siran M. Koroukian
Stock and Other Ownership Interests - American Renal Associates (I)
Research Funding - Celgene (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - Amgen; Bioentre; Boston Pharmaceuticals; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Torque; Trillium Therapeutics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Alok A. Khorana
Honoraria - Anthos Therapeutics; Bayer; Halozyme; Janssen; Medscape; Nektar; Pfizer
Consulting or Advisory Role - Anthos Therapeutics; Bayer; BMS; Janssen; Nektar; Pfizer; Sanofi
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Leap Oncology (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen